Columbia University - Herbert Irving Cancer Center

Site:	Columbia University - Herbert Irving Cancer Center
Address:
City:	New York
State:	NY
Zip:	10032
Country:	USA

Phase	Trial	Trial Status	Site Status	Drug	NCT#
1/2	Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors	Terminated	Closed	CB-839 + Talazoparib	NCT03875313
1	Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors	Suspended	Closed	Navitoclax + Sorafenib	NCT02143401
1	Study of Oral PXD101 in Patients With Advanced Solid Tumors or Lymphoma	Ongoing, but not recruiting	Closed	PXD101	NCT00413075
2	Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma	Completed	Closed	Nivolumab + Ipilimumab	NCT02500797
2	Epacadostat and Pembrolizumab in Patients With GIST Epacadostat and Pembrolizumab in Patients With GIST	Active, not recruiting	Closed	Pembrolizumab + Epacadostat	NCT03291054
2	Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study	Active, not recruiting	Closed	CB-839	NCT03872427
1	Study of the Glutaminase Inhibitor CB-839 in Solid Tumors	Active, not recruiting	Closed	CB-839	NCT02071862